Q2 2024 · 13F-HR/A
Casdin Capital, LLCholdings as filed
Filed 2024-10-18 · accession 0000919574-24-005948
$1.31B
Reported value
38
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 09062W204 | BLFS | BIOLIFE SOLUTIONS INC | $186.6M | 14.2% | 8,707,165 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $171.0M | 13.1% | 4,406,875 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $169.6M | 13.0% | 1,073,500 | Common | SOLE |
| 34385P108 | LAB | STANDARD BIOTOOLS INC | $113.2M | 8.64% | 63,959,677 | Common | SOLE |
| 81663L200 | WGS | GENEDX HOLDINGS CORP | $92.2M | 7.04% | 3,526,411 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $85.2M | 6.50% | 2,084,841 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $55.1M | 4.21% | 8,448,574 | Common | SOLE |
| 452327109 | ILMN | ILLUMINA INC | $50.1M | 3.83% | 480,000 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $44.8M | 3.42% | 2,000,000 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $41.3M | 3.15% | 170,000 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $35.2M | 2.69% | 326,378 | Common | SOLE |
| 24823R105 | DNLI | DENALI THERAPEUTICS INC | $30.2M | 2.30% | 1,300,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $27.5M | 2.10% | 700,000 | Common | SOLE |
| 30063P105 | EXK | EXACT SCIENCES CORP | $27.5M | 2.10% | 650,000 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $20.9M | 1.59% | 6,732,971 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $19.1M | 1.46% | 524,616 | Common | SOLE |
| 92337F107 | VCYT | VERACYTE INC | $18.6M | 1.42% | 857,904 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $16.8M | 1.28% | 800,000 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $15.8M | 1.21% | 675,000 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $14.9M | 1.14% | 3,059,094 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $13.2M | 1.01% | 5,190,506 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $10.8M | 0.82% | 1,000,000 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $10.2M | 0.78% | 1,188,349 | Common | SOLE |
| 901384107 | TSVT* | 2SEVENTY BIO INC | $7.7M | 0.59% | 2,000,000 | Common | SOLE |
| 192005106 | CDXS | CODEXIS INC | $6.2M | 0.47% | 2,000,000 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $5.2M | 0.40% | 296,666 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $4.3M | 0.33% | 575,000 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $3.1M | 0.24% | 150,000 | Common | SOLE |
| 00091E109 | ABSI | ABSCI CORPORATION | $3.0M | 0.23% | 973,260 | Common | SOLE |
| 40131M109 | GH | GUARDANT HEALTH INC | $2.9M | 0.22% | 100,000 | Common | SOLE |
| 74168J101 | PRME | PRIME MEDICINE INC | $1.9M | 0.14% | 367,175 | Common | SOLE |
| 69404D108 | PACB | PACIFIC BIOSCIENCES CALIF IN | $1.4M | 0.11% | 1,035,859 | Common | SOLE |
| 384747101 | GRAL | GRAIL INC | $1.2M | 0.09% | 79,999 | Common | SOLE |
| 30223G102 | EXAIEUR | EXSCIENTIA PLC | $1.1M | 0.08% | 213,900 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $976,192 | 0.07% | 261,014 | Common | SOLE |
| 37611X100 | DNA4EUR | GINKGO BIOWORKS HOLDINGS INC | $487,993 | 0.04% | 1,459,747 | Common | SOLE |
| 82933R308 | — | SINGULAR GENOMICS SYSTEMS IN | $372,890 | 0.03% | 44,129 | Common | SOLE |
| 50107A104 | KRON1USD | KRONOS BIO INC | $153,560 | 0.01% | 123,839 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.